MapLight Therapeutics

MapLight Therapeutics Assets per Share

The Total Assets per Share of MapLight Therapeutics (MPLT) as of Nov 19, 2026 is 10.57 USD. In the previous year, Total Assets per Share was 3.02 USD — a change of 250.22% (higher).

Assets per Share

10.57USD

YoY

250.22%

Last updated:

Total Assets per Share of MapLight Therapeutics is 2025 10.57 USD. Total Assets per Share of MapLight Therapeutics was 2024 3.02 USD. It decreases by 250.22% higher compared to the previous year.

The MapLight Therapeutics Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2022
0.87 USD
Jan 1, 2023
2.01 USD
Jan 1, 2024
3.02 USD
Jan 1, 2025
10.57 USD
The MapLight Therapeutics Assets per Share history
YEARAssets per ShareYoY
10.57USD+250.22%
3.02USD+49.78%
2.01USD+132.07%
0.87USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MapLight Therapeutics Stock analysis

What does MapLight Therapeutics do? MapLight Therapeutics develops novel therapeutics for brain disorders, focusing on central nervous system conditions. Its lead product ML-007C-MA combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic for schizophrenia and Alzheimer’s disease psychosis treatment. The second product ML-004 targets autism spectrum disorder symptoms as a 5-HT1B/1D agonist. The company advances preclinical programs ML-021 and ML-009, aiming to address unmet medical needs in CNS disorders. MapLight Therapeutics generates revenue through the development and potential commercialization of its product candidates. Investors and pharmaceutical partners fund the company’s clinical and preclinical research. The company’s focus on CNS disorders attracts biopharmaceutical investors seeking innovative treatments for conditions like schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. Its product pipeline targets patients with debilitating CNS conditions requiring new therapeutic options. The company’s lead candidate ML-007C-MA is designed to activate M1 and M4 muscarinic receptors in the CNS while minimizing peripheral side effects. ML-004 targets social communication deficits and irritability in autism spectrum disorder. Preclinical programs ML-021 and ML-009 represent future potential revenue streams. MapLight’s development stage indicates it is not yet generating sales but is positioned for future commercialization as clinical trials progress. MapLight Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MapLight Therapeutics stock

Total Assets per Share of MapLight Therapeutics is 10.57 USD in 2025.

Total Assets per Share of MapLight Therapeutics changed from 3.02 USD to 10.57 USD, representing a 250.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share MapLight Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — MapLight Therapeutics

All Key Metrics — MapLight Therapeutics